Tag: circulation

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

PANAMA CITY, July 24, 2025 (GLOBE NEWSWIRE) -- The cryptocurrency market faced heavy volatility as XRP dropped sharply, while LF Labs (LF Coin) attracted attention as a potential safe haven. XRP’s decline followed large wallet transfers, yet LF Labs showed resilience and gained support from a growing investor base. As panic hit XRP, LF Coin’s tokenomics and ecosystem strength helped it stand out during the correction.

SINGAPORE, July 23, 2025 (GLOBE NEWSWIRE) -- Tucked away in the lively North Bridge district, Inner Harmony is a sanctuary of wellness—blending Asian traditions with European spa innovations to deliver transformative experiences. Whether one is seeking relaxation or rejuvenation, their comprehensive suite of services caters thoughtfully to every wellness need.

MALIBU, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Magnolia Pearl, the international fashion brand known for its distinct, artisan-crafted garments, has announced the official launch of Magnolia Pearl Trade, a resale platform designed to extend the life cycle of its products while directing proceeds to charitable organizations.

Breathable joint support solutions address swelling, fatigue, and pain relief for travelers, athletes, and frontline workers this season

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.